Abstract:Objective To explore the possibility of serum α-enolase （ENO1）as a diagnostic indicator in patients with hepatitis B virus(HBV)-related hepatocellular carcinoma (HCC). Methods Ninety HCC patients（HCC group）,45 patients with liver cirrhosis (LC group),45 patients with liver fibrosis(LF group) and 45 healthy persons of physical examination (control group) from March 2018 to September 2019 were enrolled.The serum ENO1 concentration was detected by enzyme linked immunosorbent assay (ELISA) and compared among the groups.ROC analysis of ENO1 was performed,and a joint detection model was established combined with alpha fetoprotein (AFP). Results Serum ENO1 concentration in HCC group was significantly higher than that in other three groups (all P<0.01). TNM staging:the concentration of ENO1 was expressed in M(Q_L,Q_U),and which was higher in stage Ⅲ-Ⅳ patients［72.6(30.7,155.8)ng/ml］ than in stage Ⅰ-Ⅱ patients［59.8(24.5,94.9)ng/ml,U=695.5,P<0.05］;Edmondson classification: the concentration of ENO1 was lower in grade Ⅰ-Ⅱ patients［51.0(23.6, 106.0)ng/ml］ than in grade Ⅲ-Ⅳ patients［85.1(53.3,157.7)ng/ml,U=606.0,P<0.05］. AUC of combined detection of ENO1 and AFP for diagnosis of HCC was 0.853,which was superior to that of detection of ENO1(0.790) and AFP (0.823) alone. Conclusions ENO1 may be a potential diagnostic indicator of HBV-related HCC,and its level has a certain correlation with tumor staging and grading.The combined detection of ENO1 and AFP can increase the accuracy of HCC diagnosis.